Tilmann has a PhD in Biochemistry from the Robert-Koch-Institute in Berlin, where he worked on host-pathogen interaction. Afterwards, he joined the laboratory of Giulio Superti-Furga at the Research Center for Molecular Medicine (CeMM) in Vienna to study the innate immune response to viral infection as a post-doctoral fellow. Following that, Tilmann was hired as a Principal Scientist to establish the newly founded biotech company Haplogen which was centered on exploiting haploid human cells for genetic studies. He stayed with Haplogen and, later on, Haplogen Genomics for four years, serving as Head of Research and Chief Scientific Officer. Following the acquisition of Haplogen Genomics by Horizon Discovery, Tilmann became R&D director, using CRISPR/ Cas technology for cell line engineering and product development. Since January 2017, Tilmann is in charge of Horizon's innovation agenda where he has the mandate to innovate Horizon’s technology core and devise new applications of the CRISPR/Cas technology.